On-Demand CME Videos
Therapeutic Hotline: Expert Perspectives on IL17 Inhibitors in Targeted Management of Inflammatory Skin Disorders
About
To find out the correct answer, click "Start Activity."
Your 27-year-old patient with a 15-year history of psoriasis is anxious to find treatment that can improve the psoriatic lesions before she gets married next week. What do you tell her about the percentage of patients who on average achieve an improvement (PASI 75) after 4 weeks of bimekizumab?
a. 20%
b. 50%
c. 75%
d. 90%
This activity is supported by an educational grant from UCB.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
August 15, 2023
August 15, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Explain the role of the IL-17 pathway in the pathophysiology of chronic inflammatory dermatologic disorders
Review data for IL-17 inhibitors for the management of inflammatory dermatologic disorders
Discuss strategies to educate patients about IL-17 inhibitors and incorporate these agents into clinical care
Intended Audience
Faculty
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Ronald Vender, MD, FRCPC
Dermatrials Research Inc & Venderm Consulting
Associate Clinical Professor of Medicine
McMaster University
Hamilton, Canada
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.
Advisory Board/Consultant: Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Kabi-Care, Leo, Lilly, Merck,
Novartis, Palladin, Pfizer, Sandoz, SUN, UCB, Viatris-Mylan
Grant/Research Support: Abbvie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Celgene,
Centocor, Dermira, Dermavant, Galderma, GSK, Innovaderm, Janssen, Leo, Lilly, Meiji, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, Takeda, UCB
Speaker's Bureau: Abbvie, Actelion, Amgen, Arcutis, Bausch-Health, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Leo, Lilly, Merck, Novartis, Pfizer, Sun, UCB
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.